Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Gross Profit (2017 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Gross Profit for 8 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 91.0% year-over-year to $18.1 million, compared with a TTM value of $47.7 million through Dec 2025, up 47.47%, and an annual FY2025 reading of $47.7 million, up 47.47% over the prior year.
  • Gross Profit was $18.1 million for Q4 2025 at Agios Pharmaceuticals, up from $11.2 million in the prior quarter.
  • Across five years, Gross Profit topped out at $18.1 million in Q4 2025 and bottomed at $493000.0 in Q1 2022.
  • Average Gross Profit over 4 years is $7.3 million, with a median of $6.9 million recorded in 2023.
  • The sharpest move saw Gross Profit surged 925.35% in 2023, then increased 1.04% in 2025.
  • Year by year, Gross Profit stood at $3.9 million in 2022, then surged by 67.23% to $6.5 million in 2023, then skyrocketed by 45.31% to $9.5 million in 2024, then surged by 91.0% to $18.1 million in 2025.
  • Business Quant data shows Gross Profit for AGIO at $18.1 million in Q4 2025, $11.2 million in Q3 2025, and $10.8 million in Q2 2025.